Prognostic value of CD103+ tumor-infiltrating lymphocytes in bladder cancer: A systematic review and meta-analysis.

Urol OncolAug 22, 2026 (epub)
Clinical ResearchOncology (Medical)Urology

Eduardo Germano Teixeira, Lucas Antônio Fernandes Torres, Maria Luiza Rodrigues Defante et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the prognostic significance of CD103+ tumor-infiltrating lymphocytes in bladder cancer, focusing on muscle-invasive and metastatic cases. The analysis included three studies with six cohorts, revealing that high CD103+ infiltration is associated with improved overall survival (HR: 0.50, 95% CI: 0.30-0.83), particularly in patients undergoing surgery with adjuvant chemotherapy.

Key findings

  • High CD103+ infiltration was associated with improved overall survival (HR: 0.50, 95% CI: 0.30-0.83).
  • Patients undergoing surgery with adjuvant chemotherapy showed a significant survival benefit (HR: 0.20).
  • Muscle-invasive bladder cancer patients had a pronounced benefit (HR: 0.27) compared to metastatic cases (HR: 0.79).
  • Immunohistochemistry cohorts demonstrated a numerically larger effect than ITGAE mRNA cohorts.

Why it matters

Understanding the role of CD103+ tumor-infiltrating lymphocytes could enhance prognostic assessments in bladder cancer, potentially guiding treatment decisions and improving patient outcomes.

Source

PubMed · PMID 42632294

Published in Urol Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.